论文部分内容阅读
现认为肝性脑病(HE)可能是GABA/苯二氮(艹卓)(Bz)抑制性神经递质系统改变所致。本文报道采用前瞻性随机双盲交叉试验观察一种特异的Bz受体拮抗剂氟马西尼(flumazenil)治疗肝硬化并发肝昏迷的疗效。 病人与方法:患者18～70岁,肝硬化经肝活检证实,HE处于第4期。患者随机归于治疗组和安慰剂组,按双盲法开始治疗。在治疗前30分钟和开始用药时评估基线神经状况。用
It is thought that hepatic encephalopathy (HE) may be caused by the change of GABA / benzodiazepine (Bz) inhibitory neurotransmitter system. This article reports the prospective randomized double-blind crossover study to observe the efficacy of a specific Bz receptor antagonist flumazenil in the treatment of hepatic cirrhosis with hepatic coma. Patients and Methods: Patients 18 to 70 years of age, cirrhosis confirmed by liver biopsy, HE in the first four. Patients were randomly assigned to treatment and placebo groups and were treated by double-blind therapy. Baseline neurological status was assessed 30 minutes prior to treatment and when medication was started. use